GeoVax Labs, Inc. (NASDAQ: GOVX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $18.00 price target on the stock.
GeoVax Receives Notice of Allowance For Cancer Vaccine Patent [Yahoo! Finance]
GeoVax Receives Notice of Allowance For Cancer Vaccine Patent
GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference [Yahoo! Finance]
GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference